Guardant Health is a pioneering biotechnology company dedicated to transforming cancer care through advanced blood-based diagnostics. By analyzing circulating tumor DNA (ctDNA) in blood samples, Guardant Health's innovative tests enable early cancer detection, comprehensive genomic profiling, and monitoring of treatment responses, thereby facilitating personalized treatment strategies and improving patient outcomes.
Key Features and Functionality:
- Guardant360® Liquid CDx: An FDA-approved liquid biopsy test that analyzes a broad panel of genomic alterations, providing critical insights for guiding targeted therapies in advanced solid tumors.
- Guardant360® Tissue: A comprehensive tissue-based genomic profiling test that complements liquid biopsy results, offering a complete genomic landscape of the tumor.
- Guardant Reveal®: A blood test designed for minimal residual disease (MRD) detection and recurrence monitoring in early-stage cancers, enabling timely intervention and personalized treatment adjustments.
- Shield™: A blood-based screening test for colorectal cancer, offering a non-invasive alternative to traditional methods, thereby increasing screening compliance and early detection rates.
Primary Value and Solutions Provided:
Guardant Health's suite of products addresses critical challenges in oncology by offering non-invasive, accurate, and timely diagnostic solutions. These tests empower healthcare providers to detect cancer at its earliest stages, tailor treatments based on the tumor's unique genomic profile, and monitor disease progression or recurrence with ease. By reducing the need for invasive procedures and enabling real-time insights into tumor dynamics, Guardant Health enhances patient care, improves clinical outcomes, and contributes to the advancement of precision oncology.
